The landscape of psychiatric medicine is shifting as LB Pharmaceuticals moves its promising LB-102 into pivotal Phase 3 trials. Known as the NOVA-2 study, this research aims to validate a …
Mental HealthBreaking NewsGeneralGlobal Breaking NewsHealthMedical Advances and ResearchResearch and DiscoveriesTechnologyTodays HeadlinesTop Headlines
Schizophrenia Treatment Breakthrough: LB Pharmaceuticals Launches Pivotal Phase 3 NOVA-2 Trial for LB-102
Discover how the first-in-class benzamide LB-102 is redefining recovery by targeting cognitive symptoms and minimizing traditional antipsychotic side effects.